Forbes Africa news story
In February, the first trial participants received the BRILLIANT 011 experimental HIV vaccine – a first-in-human clinical trial by the BRILLIANT Consortium (BRinging Innovation to cLinical and Laboratory research to end HIV In Africa through New vaccine Technology) – led by the South African Medical Research Council (SAMRC).
However, according to Glenda Gray, pediatrician, HIV researcher and professor at the University of the Witwatersrand, it is more than a scientific milestone; the trial represents a structural shift in Africa’s role in global vaccine development.
“This isn’t just about being first-in-human,” says Gray. “It’s about leading fundamental vaccine science on the continent.”
Read the full news story here.
Source : Forbes Africa
Related HIV and Co-Infections News
-
NIH-funded breakthrough shrinks CRISPR for precision delivery in the body
-
[Press release] US and Global Fund expand commitment to long-acting HIV prevention as country rollout of lenacapavir accelerates
-
University of Manchester: Scientists develop a cheaper and more sustainable way to manufacture breakthrough HIV drug lenacapavir
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.